Stem cells are a class of undifferentiated biological cells of a multicellular organism that have potential to produce indefinite cells of the same type, from which certain type of cells (replication) can be produced by differentiation in the body through early life and growth.
Global TNF inhibitor market accounted for US$ 75,578.9 Mn in 2021 and expected to attain US$ 3,15,486.4 Mn in 2033 growing at a CAGR of 16.5% during the forecast period from 2025 to 2033.
Global biologics market accounted for market value of US$ 254.9 Bn in 2017 and expected to attain US$ 580.5 Bn by 2026. Recombinant therapeutic proteins contributed largest market share in 2017 while cellular and gene therapies exhibited fastest annual growth during the forecast period from 2018 to 2026.
Huber needles find wide application in blood transfusions, chemotherapy, drug delivery, parenteral nutrition, surgical procedures such as angioplasty and diagnostic procedures such as contrast CT scans. Therefore wide application areas predominantly drive the Huber needles market globally.
Epigenetics is a term referred to the study of long-term changes in gene expression, which may or may not be heritable, and do not involve the changes to the DNA sequence. It is estimated that epigenetics market will grow at a double digit CAGR over the forecast period from 2018 to 2026. Some major factors assisting the market growth are increasing awareness about epigenetics in different medical fields, growing funding for research and development activities and increasing prevalence of complex diseases such as cancer. Conversely, lack of widespread availability of skilled professionals and existence stringent regulatory framework governing the field of epigenetics and genetic research restrain the market growth.
GI Stool Testing Market Is Projected to Expand At A CAGR Of XX% Between 2025 And 2033. Stools tests are performed to diagnose the GI tract disorders and aid in the detection of parasites infection, bleeding obstruction, and inflammation. Stools tests can further be utilized for diagnosis of colorectal cancer or presence of pathogens such as Rotavirus, C. difficile, H. pylori among others in the GI tract.
Patient positioning systems (PPS) play a significant role in healthcare settings as a prerequisite for assistance in surgical procedures and recovery. Optimal patient positioning ensures finest access to the surgical sites and prevents any possibility of nerve damage or pressure ulcers; thus, resulting in faster rehabilitation, recovery and better outcomes. Patient positioners prove significant in robotic surgery where patient stability is of upmost importance. Rising number of robotic surgical procedures have spurred the demand for patient positioning systems.
The CAR-T cell therapy market was valued at US$ 174.24 Mn in 2021 and projected to exhibit double digit compound annual growth rate (CAGR) of 35.5% during the forecast period from 2025 to 2033. Scientist have encountered the biggest challenge in the treatment of cancer is that the cancer cells with the disease progression usually become invisible to the body’s defense mechanism. Immunotherapy is the future in the treatment of cancer where the immune cells are genetically engineered in order to recognize the biomarkers of cancerous cells, target them and kill them.
Neuroendocrine tumors can be benign or malignant. This condition rarely shows any symptoms and occurs usually in the pancreas, lungs, gastrointestinal tracts, and other organs of the body. According to the World Health Organization, the incidence of malignant neuroendocrine tumors is 0.2 per 100,000 people.
American Brain Tumor Association 2021 report cites that cancer is the second largest cause for death globally responsible for the death of approximately 8.8 million patients. World Health Organization predicts the growth of cancer incidence to reach 70% in next 20 years. Gamma knife devices faces stringent market competition by other types of radiosurgery such as Linear Accelerator Systems (LINAC) and Cyclotron.
The oncology drugs market includes pharmaceutical products and advanced therapies used to treat cancer. Major treatment classes include chemotherapy, targeted therapy, immunotherapy, hormonal therapy, monoclonal antibodies, antibody-drug conjugates, cancer vaccines and cell-based treatments. These drugs are used across lung, breast, colorectal, prostate, blood, skin, ovarian, liver and other cancer indications.
The global cancer and oncology drugs market is expected to record strong growth through 2035. One current industry estimate projects the market to increase from approximately USD 214.70 billion in 2026 to USD 554.69 billion by 2035, representing a compound annual growth rate of 11.17%. Growth is supported by targeted treatments, developments in proteomics and continued demand for more effective cancer therapies.
The increasing global incidence of cancer is a major market driver. Population ageing, tobacco use, obesity, environmental exposure and lifestyle-related risk factors are contributing to a growing patient population. Improved screening and diagnostic technologies are also identifying more patients at earlier stages, increasing the number of individuals eligible for pharmaceutical treatment.
Targeted therapies represent an important market segment. These drugs act on specific genes, proteins or pathways involved in tumour development. Biomarker testing and companion diagnostics help physicians identify patients who are more likely to respond to particular treatments. Precision oncology is therefore increasing the connection between diagnostic testing and drug selection.
Immunotherapy continues to change cancer treatment by helping the immune system identify and attack tumour cells. Immune checkpoint inhibitors, CAR-T cell therapies and cancer vaccines are being studied across multiple solid and blood cancers. Combination therapies using immunotherapy with chemotherapy, targeted drugs or radiation are also expanding as companies seek to improve treatment response and patient survival.
Other major trends include antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals and personalized cancer vaccines. Artificial intelligence is being used for target identification, molecule screening, clinical-trial planning and analysis of patient data. Biosimilars are gaining importance as patents expire for established oncology biologics, potentially improving access and increasing price competition.
Market expansion may be restrained by high treatment costs, adverse effects and unequal access to cancer care. Oncology drugs require extensive clinical testing, and unsuccessful trials can result in substantial development losses. Drug resistance may reduce long-term treatment effectiveness and create demand for additional therapies. Reimbursement restrictions and complex regulatory requirements can also delay patient access.
North America remains a major market due to high cancer treatment expenditure, research activity and access to new medicines. Europe maintains a significant position, while Asia-Pacific is expected to record strong growth as cancer incidence, healthcare investment and access to treatment increase.
Acute Market Reports provides oncology drugs market research covering drug classes, cancer indications, routes of administration, distribution channels, development pipelines, competitive conditions and regional opportunities. These reports help pharmaceutical companies, biotechnology firms, investors and healthcare organizations assess market demand and growth prospects through 2035.